Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
GARP vs IBB: how they differ
GARP and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
iShares MSCI USA Quality GARP ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, GARP and IBB hold 0% of their money in the same securities at the same weight.
| Holding | GARP | IBB |
|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 0.05% | 3.12% |
| INCYTE CORP | 0.05% | 1.75% |
| NATERA INC | 0.05% | 2.89% |
| NEUROCRINE BIOSCIENCES INC | 0.04% | 1.30% |
| Only in GARP | Only in IBB |
|---|---|
| KLA CORP 6.46% | Vertex Pharmaceuticals, Inc. 8.09% |
| MICRON TECHNOLOGY INC 6.07% | Amgen, Inc. 7.84% |
| APPLE INC 4.44% | Gilead Sciences, Inc. 6.85% |
| NVIDIA CORP 4.16% | Regeneron Pharmaceuticals, Inc. 4.91% |
| MICROSOFT CORP 4.10% | Argenx SE 3.76% |
| BROADCOM INC 3.96% | Revolution Medicines, Inc. 2.78% |
| LAM RESEARCH CORP 3.79% | Biogen, Inc. 2.47% |
| ELI LILLY & COMPANY 3.73% | Illumina, Inc. 2.07% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| GARP iShares MSCI USA Quality GARP ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | iShares |
| What it is | MSCI USA Quality GARP | Biotechnology |
| Total return, 1 year | +29.5% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +12.0 pts | +24.0 pts |
| Expense ratio | 0.15% | 0.44% |
| Already in the S&P 500 | 94.4% | 35.6% |
| Holdings | 131 | 248 |
GARP in plain words
GARP is an index equity fund tracking the MSCI USA Quality GARP. Over the year to Sep 11, 2026 it returned +29.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for Jun 30, 2026, 94% of the fund by weight is stocks the S&P 500 also holds, across 131 positions, with the top ten at 43.8%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, GARP or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, GARP returned +29.5% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, GARP or IBB?
- GARP charges 0.15% a year and IBB charges 0.44%, so GARP is cheaper. Fees come from each fund's prospectus.
- How much do GARP and IBB overlap with the S&P 500?
- By their latest filed holdings, 94% of GARP and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, GARP against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/GARP-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources